$37.00Day Range$38.38
Key Statistics
Market Cap
$2.67B
Shares Outstanding
70.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 5, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$38.12
Day High
$38.38
Day Low
$37.00
Volume
829.0K
VWAP
$37.73
Prev Close
$38.06
Transactions
--
Acc. Volume
--
About Pharvaris N.V. Ordinary Shares
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Identifiers
- CIK
- 0001830487
- Ticker Root
- PHVS
About Pharvaris N.V. Ordinary Shares (PHVS) Stock
Pharvaris N.V. Ordinary Shares (PHVS) closed the 2026-09-16 session at $37.55, down 1.34% versus the previous close (-0.51). The stock opened at $38.12 and traded between $37.00 and $38.38 during that session. Session trading volume was 829K shares. The volume-weighted average price (VWAP) is $37.73.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Pharvaris N.V. Ordinary Shares has a market capitalization of $2.67 billion. PHVS is listed on the XNAS exchange. The company employs approximately 129 people. The recorded listing date is 2021-02-05.
On this page you can find market PHVS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.